What are the reasons why cabergoline is banned in China?

Cabergoline (Cabergoline) is a dopamine receptor agonist mainly used to treat a variety of diseases, especially symptoms related to hyperprolactinemia. As a selective dopamine D2 receptor agonist, cabergoline regulates hormone secretion in the body by simulating the effects of dopamine, thereby achieving therapeutic effects. Clinically, it is often used to reduce the level of prolactin in the serum, thereby improving symptoms such as irregular menstruation and galactorrhea caused by high prolactin. However, despite its wide application in the medical field, cabergoline faces a ban on sales in China.

The reason why cabergoline is banned in China is mainly related to the safety of the drug and regulatory policies. On the one hand, cabergoline may cause some side effects, including cardiovascular problems, digestive system reactions, and neurological discomfort. Long-term use of this drug may cause damage to heart valves and increase the risk of cardiovascular disease, especially in patients with underlying medical conditions. Regulators are wary of its use because of these potentially serious side effects.

On the other hand, domestic approval and supervision of drugs are relatively strict, especially when it comes to hormone drugs and drugs that affect the human endocrine system. In terms of clinical data and drug safety evaluation, cabergoline's clinical trials and marketing promotion in China were restricted, resulting in its failure to obtain marketing authorization. In addition, the continuous improvement of China's drug administration laws and the emphasis on drug safety have also prompted regulatory agencies to take measures to ban the sale of certain drugs to protect the health of patients.

Reference materials:https://my.clevelandclinic.org/health/drugs/20863-cabergoline-tablets